These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34119515)

  • 1. The Association Between Pleural Fluid Exposure and Survival in Pleural Mesothelioma.
    Asciak R; Kanellakis NI; Bibby A; Kidd A; Gerry S; Mercer R; Maskell N; Blyth KG; Fsadni P; Montefort S; Psallidas I; Rahman NM
    Chest; 2021 Nov; 160(5):1925-1933. PubMed ID: 34119515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.
    Zhang S; Zhang Y; Feng W; Shi Z; Shi H; Zhang Y
    Thorac Cancer; 2021 Dec; 12(24):3304-3309. PubMed ID: 34704370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
    Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
    Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Value of Computed Tomography Imaging Features in Malignant Pleural Mesothelioma.
    Fortin M; Cabon E; Berbis J; Laroumagne S; Guinde J; Elharrar X; Dutau H; Astoul P
    Respiration; 2020; 99(1):28-34. PubMed ID: 31655816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Systemic Anticancer Therapy Associated With Higher Rates of Malignant Pleural Effusion Control in People With Pharmacologically Sensitive Tumors?: A Retrospective Analysis of Prospectively Collected Data.
    Holling N; Patole S; Medford ARL; Maskell NA; Bibby AC
    Chest; 2021 Nov; 160(5):1915-1924. PubMed ID: 34023321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
    Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
    BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.
    Matthews C; Freeman C; Sharples LD; Fox-Rushby J; Tod A; Maskell NA; Edwards JG; Coonar AS; Sivasothy P; Hughes V; Rahman NM; Waller DA; Rintoul RC
    BMJ Open Respir Res; 2019; 6(1):e000368. PubMed ID: 30687504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma.
    Dozin B; Carbotti G; Roncella S; Ferro P; Dessanti P; Canessa PA; Ferrini S; Fabbi M
    Cancer Immunol Immunother; 2021 Nov; 70(11):3349-3355. PubMed ID: 34003301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival.
    Lumachi F; Mazza F; Ermani M; Chiara GB; Basso SM
    Anticancer Res; 2012 Nov; 32(11):5071-4. PubMed ID: 23155281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: A single-centre experience.
    Leemans J; Dooms C; Ninane V; Yserbyt J
    Respirology; 2018 Jun; 23(6):613-617. PubMed ID: 29320805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
    Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
    Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases.
    Senyiğit A; Bayram H; Babayiğit C; Topçu F; Balci AE; Satici O
    Respiration; 2000; 67(6):623-9. PubMed ID: 11124644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically important associations of pleurodesis success in malignant pleural effusion: Analysis of the TIME1 data set.
    Mercer RM; Macready J; Jeffries H; Speck N; Kanellakis NI; Maskell NA; Pepperell J; Saba T; West A; Ali N; Corcoran JP; Hallifax RJ; Psallidas I; Asciak R; Hassan M; Miller RF; Rahman NM
    Respirology; 2020 Jul; 25(7):750-755. PubMed ID: 31846131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.
    Thomas R; Fysh ETH; Smith NA; Lee P; Kwan BCH; Yap E; Horwood FC; Piccolo F; Lam DCL; Garske LA; Shrestha R; Kosky C; Read CA; Murray K; Lee YCG
    JAMA; 2017 Nov; 318(19):1903-1912. PubMed ID: 29164255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival in patients with malignant pleural effusion undergoing talc pleurodesis.
    Hassan M; Mercer RM; Maskell NA; Asciak R; McCracken DJ; Bedawi EO; Shaarawy H; El-Ganady A; Psallidas I; Miller RF; Rahman NM
    Lung Cancer; 2019 Nov; 137():14-18. PubMed ID: 31521977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses.
    Paajanen J; Laaksonen S; Ilonen I; Vehmas T; Mäyränpää MI; Sutinen E; Kettunen E; Salo JA; Räsänen J; Wolff H; Myllärniemi M
    Clin Lung Cancer; 2020 Nov; 21(6):e633-e639. PubMed ID: 32624414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients.
    Ak G; Metintaş M; Yildirim H; Metintaş S; Dündar E; Erginel S; Alataş F
    Tuberk Toraks; 2009; 57(1):22-31. PubMed ID: 19533434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.
    Gutierrez-Sainz L; Cruz P; Martinez-Recio S; Higuera O; Esteban-Rodriguez MI; Arias-Lotto F; Gonzalez RA; De Castro-Carpeño J
    Clin Transl Oncol; 2021 Oct; 23(10):2030-2035. PubMed ID: 33837910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.